1. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson, Nick Carter, Stephan Duparc, Zul Premji, Alfred B. Tiono, and Lucio Luzzatto Blood Volume 120(20):4123-4133 November 15, 2012 ©2012 by American Society of Hematology

2. Change in hemoglobin concentrations relative to values obtained at day 1 in children receiving a dapsone-containing combination or AL for the treatment of falciparum malaria. Allan Pamba et al. Blood 2012;120:4123-4133 ©2012 by American Society of Hematology

3. Hemolytic anemia in G6PD-deficient children with malaria receiving therapy with a dapsone- containing combination. Allan Pamba et al. Blood 2012;120:4123-4133 ©2012 by American Society of Hematology

4. Variability in hemoglobin levels in individual patients. Allan Pamba et al. Blood 2012;120:4123-4133 ©2012 by American Society of Hematology

5. Blood smears from a 3-year-old boy with acute malaria and G6PD deficiency treated with chlorproguanil-dapsone. Allan Pamba et al. Blood 2012;120:4123-4133 ©2012 by American Society of Hematology

6. The G6PD genotype was a major determinant of the severity of anemia in children given dapsone. Allan Pamba et al. Blood 2012;120:4123-4133 ©2012 by American Society of Hematology

7. Illustrative examples of the hematologic impact of dapsone in individual patients with falciparum malaria. Allan Pamba et al. Blood 2012;120:4123-4133 ©2012 by American Society of Hematology